Skip to main content
. 2022 Dec 7;6(1):76–87. doi: 10.1021/acsptsci.2c00165

Figure 4.

Figure 4

Peptide KKP effectively degrades the Keap1 protein. (A) Western blot analysis of the Keap1 protein level in HSC-T6 cells treated with different concentrations of KKP1 for 4 h. (B) Densitometric quantification of the Keap1 protein in the blots shown in (A); the data in the graph are means ± SEM of three independent measurements. (C) Western blot analysis of the Keap1 protein level in HSC-T6 cells incubated with 0.75 μM of KKP1, KKP2, and KKPs at 1, 2, 4, 8, and 16 h respectively. (D) Densitometric quantification of the Keap1 protein in the blots shown in (C). The data in the graph are means ± SEM of three independent measurements. (E) Corresponding p-value plot between data pairs presented in (C). ANOVA was used to compare the differences between the control and experimental values in the 4 and 8 h treatment groups. (F) Bar graph showing the AUC analysis of (D). (G) Western blot analysis of the Keap1 protein level in the HSC-T6 cells incubated with the proteasome inhibitor MG132 (10 μM, 4 h) before 7.5 μM of KKP1, KKP2, and KKPs treatment. (H) Densitometric quantification of the Keap1 protein in the blots shown in (E). The data in the graph are means ± SEM of three independent measurements. (I) The bar graph shows the AUC analysis of (F).